PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma

INTRODUCTION: Cetuximab, a monoclonal antibody to the epidermal growth factor receptor (EGFR), extends survival in combination with standard therapy in head and neck squamous cell carcinoma (HNSCC). However, as effects are modest, and patients experience side effects, a biomarker to predict resistan...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oral Oncol
Asıl Yazarlar: Eze, Nnamdi, Lee, Ju-Whei, Yang, Dong-Hua, Zhu, Fang, Neumeister, Veronique, Sandoval-Schaefer, Teresa, Mehra, Ranee, Ridge, John A., Forastiere, Arlene, Chung, Christine H., Burtness, Barbara
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6855599/
https://ncbi.nlm.nih.gov/pubmed/30926065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2019.02.026
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller